Comparative Pharmacology
Head-to-head clinical analysis: MUPIROCIN versus PROLOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MUPIROCIN versus PROLOPRIM.
MUPIROCIN vs PROLOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
Inhibits bacterial dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA, RNA, and protein synthesis.
Apply a small amount of 2% ointment or cream to affected area three times daily for 5 to 14 days.
100 mg orally twice daily or 200 mg orally once daily.
None Documented
None Documented
Intravenous: ~30 min (0.5 h). Topical: systemically absorbed amount negligible, local half-life not defined.
Clinical Note
moderateMupirocin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin."
Terminal elimination half-life is 8-10 hours in normal renal function; prolonged (>20 hours) in significant renal impairment.
Renal: <1% unchanged (topical); hepatic metabolism to monic acid, eliminated renally and fecally. After IV administration, 60-70% renal, 20-30% fecal/biliary.
Primarily renal (80-90% as unchanged drug); less than 5% as metabolites; fecal excretion negligible.
Category A/B
Category C
Antibiotic
Antibiotic